ANTENGENE CORP. DL-0001
Research ANTENGENE CORP. DL-0001 (722) on Bullrun: market cap EUR 285.87M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker722
- ExchangeF
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 285.87M
- Financial periodFY2025
- RevenueCNY 105.34M
- Revenue growth14.6%
- Net income-CNY 239.13M
- Free cash flow-CNY 178.86M
- Gross margin83.6%
Valuation Snapshot
latest market cap is EUR 285.87M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 105.34M | -CNY 239.13M | -CNY 178.86M | 83.6% | -0.38 | CNY 718.25M | CNY 257.51M | CNY 642.43M |
| FY2024 | CNY 91.95M | -CNY 319.25M | -CNY 382.58M | 81.9% | -0.51 | CNY 884.54M | CNY 249.44M | CNY 850.80M |
| FY2023 | CNY 67.31M | -CNY 581.18M | -CNY 778.87M | 81.7% | -0.94 | CNY 1.18B | CNY 201.02M | CNY 1.15B |
| FY2022 | CNY 160.14M | -CNY 601.49M | -CNY 671.56M | 82.4% | -0.97 | CNY 1.78B | CNY 57.96M | CNY 1.71B |
| FY2021 | CNY 28.77M | -CNY 655.53M | -CNY 627.94M | 84.1% | -1.05 | CNY 2.27B | CNY 14.81M | CNY 2.39B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-27 | EUR 285.87M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About ANTENGENE CORP. DL-0001
Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The company's commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is ANTENGENE CORP. DL-0001's market cap?
ANTENGENE CORP. DL-0001's market capitalization is EUR 285.87M.
What does ANTENGENE CORP. DL-0001 do?
Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The company's commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients.